Oppenheimer Downgraded Spero Therapeutics to Perform From Outperform, Shares Down 4.67%.
<p>Oppenheimer downgraded <a href='https://financialmodelingprep.com/financial-summary/SPRO'>Spero Therapeutics, Inc. (NASDAQ:SPRO) to perform from outperform, providing the following key point for that decision:</p>
<p>(1)	Stock trades near prior $20 price target</p>
<p>(2)	unfavorable upside/downside from Revenue Interest Financing (RIF) into NDA review and commercial launch of Tebipenem,</p>
<p>(3)	expectation for RIF financing covenants to complicate business development (relative to issuing equity or bank debt) including a potential sale of SPRO. </p>
<p>While the analysts acknowledge all companies should be managed for long-term value creation, with delay in SPR720 due to clinical hold and the prospect of 3–5 years of commercial organization only selling one product (Tebipenem), they view the company as likely to be either an acquirer of assets or seller of the company over the next 36 months.</p>
<p>Shares of Spero Therapeutics closed 4.67% lower on Friday.</p>

NASDAQ:SPRO